Ayahuasca and Depression: Preliminary Clinical Findings

A double-blind, placebo-controlled trial conducted at the University of São Paulo (Palhano-Fontes et al., 2019, n = 29) found that a single ayahuasca session produced significant reductions in depression scores within 24 hours, with effects persisting at 7 days. The treatment group showed a mean reduction of 10.8 points on the MADRS scale, compared to 3.2 in the placebo group (p = 0.04).

What makes these findings notable is the speed of onset. Conventional antidepressants (SSRIs) typically require 2–6 weeks to produce clinical effects. Ayahuasca's rapid action — comparable to ketamine's — suggests a mechanism distinct from monoamine modulation, possibly involving sigma-1 receptor activation and BDNF (brain-derived neurotrophic factor) upregulation.

The sample is small and replication is needed. The authors caution that ayahuasca is not a self-administered treatment; the trial was conducted in a controlled setting with experienced facilitators, and the brew's variable pharmacology (DMT content and MAOI activity differ between preparations) makes standardization challenging. The findings are promising but preliminary, and should not be taken as a recommendation for self-treatment.